Research programme: PFKFB3 inhibitors - Advanced Cancer TherapeuticsAlternative Names: 3PO; PFKFB3 inhibitors - Advanced Cancer Therapeutics
Latest Information Update: 12 Oct 2012
At a glance
- Originator University of Louisville
- Developer Advanced Cancer Therapeutics
- Class Small molecules
- Mechanism of Action PFKFB3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Glioblastoma